RT Journal Article
T1 Determination of Exosome Mitochondrial DNA as a Biomarker of Renal Cancer Aggressiveness.
A1 Arance, Elena
A1 Ramirez, Viviana
A1 Rubio-Roldan, Alejandro
A1 Ocaña-Peinado, Francisco M
A1 Romero-Cachinero, Catalina
A1 Jodar-Reyes, Ana Belen
A1 Vazquez-Alonso, Fernando
A1 Martinez-Gonzalez, Luis Javier
A1 Alvarez-Cubero, Maria Jesus
K1 biomarker
K1 exosome
K1 extracellular vesicles
K1 mitochondrial DNA
K1 renal cancer
AB Here, the role of non-invasive biomarkers in liquid biopsy was evaluated, mainly in exosomes and mitochondrial DNA (mtDNA) as promising, novel, and stable biomarkers for renal cell carcinoma (RCC). A total of 140 fractions (named from B to F) obtained by ultracentrifugations of whole blood samples from 28 individuals (13 patients and 15 controls) were included. Nanoparticle Tracking Analysis (NTA) was conducted to characterized exosomal fraction. Subsequently, an analysis of digital PCR (dPCR) using the QuantStudio™ 3D Digital PCR platform was performed and the quantification of mtDNA copy number by QuantStudioTM 12K Flex Real-Time PCR System (qPCR) was developed. Moreover, Next Generation Sequencing (NGS) analyses were included using MiSeq system (Illumina, San Diego, CA, USA). An F fraction, which contains all exosome data and all mitochondrial markers, was identified in dPCR and qPCR with statistically significant power (adjusted p values ≤ 0.03) when comparing cases and controls. Moreover, present analysis in mtDNA showed a relevant significance in RCC aggressiveness. To sum up, this is the first time a relation between exosomal mtDNA markers and clinical management of RCC is analyzed. We suggest a promising strategy for future liquid biopsy RCC analysis, although more analysis should be performed prior to application in routine clinical practice.
PB MDPI AG
SN 2072-6694
YR 2021
FD 2021-12-28
LK http://hdl.handle.net/10668/20865
UL http://hdl.handle.net/10668/20865
LA en
NO Arance E, Ramírez V, Rubio-Roldan A, Ocaña-Peinado FM, Romero-Cachinero C, Jódar-Reyes AB, et al. Determination of Exosome Mitochondrial DNA as a Biomarker of Renal Cancer Aggressiveness. Cancers (Basel). 2021 Dec 31;14(1):199.
NO This study is partially supported by ID#53169721 project funded by Pfizer and the exosomes characterization was financed thanks to the grant PY20_00241 (FEDER/Junta de Andalucía-Regional Ministry of Economic Transformation, Industry, Knowledge and Universities).
DS RISalud
RD Apr 7, 2025